Advertisement

Topics

Madison Vaccines Announces First Patient Dosed In An Expanded Combination Trial Of MVI-816 Plus Keytruda?? For Metastatic, Treatment-Resistant Prostate Cancer

20:00 EDT 1 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Madison Vaccines Announces First Patient Dosed In An Expanded Combination Trial Of MVI-816 Plus Keytruda?? For Metastatic, Treatment-Resistant Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "Madison Vaccines Announces First Patient Dosed In An Expanded Combination Trial Of MVI-816 Plus Keytruda?? For Metastatic, Treatment-Resistant Prostate Cancer"

Quick Search
Advertisement